WIN 51711 (5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methylisoxazole), a new antipicornavirus drug, is a potent inhibitor of human entero-and rhinoviruses at concentrations not inhibitory to HeLa cell growth. In plaque reduction assays, WIN 51711 reduced plaque formation by 9 enteroviruses and 33 rhinoviruses, with MICs of 0.004 to 0.17 and 0.004 to 6.2 p,g/ml, respectively. Addition of WIN 51711 to infected cells at concentrations of 0.02 to 5.0 ,ug/ml reduced the yield of picornaviruses by 90%. Other RNA viruses (nonpicornaviruses) and DNA viruses were unaffected by the compound.
Currently, no drugs are available for the treatment of human diseases caused by the rhino-and enterovirus members of the picornavirus family (7) . Based on the finding that arildone is a potent inhibitor of a limited number of enteroviruses in vitro (1, 2) and in vivo (4), a series of analogs was synthesized in an effort to discover a systemically active compound with broad-spectrum activity against the causative agents of viral meningitis, hepatitis A, acute hemorrhagic conjunctivitis, and the common cold (6, 9) . This report describes the potent in vitro activity of WIN 51711 ( Fig. 1 ) against representative serotypes of both enteroviruses and rhinoviruses.
MATERIALS AND METHODS Media and solutions. The following media and solutions were used: minimal essential medium (MEM), medium 199 (M-199), and 2x M-199 (Flow Laboratories, Inc., McLean, Va.) with 10% Bobby calf serum from GIBCO Laboratories (Grand Island, N.Y.), 1% SeaKem agarose in water (FMC Corp., Marine Colloids Div., Rockland, Maine), 3 mg of DEAE-dextran per ml, 3 M MgCl2, 3% formaldehyde with 2% sodium acetate in water for fixing, and 0.25% crystal violet in fixing solution for staining. A set of 200x stock solutions of WIN 51711 was prepared in Me2SO (dimethyl sulfoxide) and diluted in M-199 to achieve final concentrations of 0.001 to 6.2 ,ug/ml. Viruses (Fig. 2) . The 90% effective doses ranged from approximately 0.02 ,ug/ml for poliovirus 2 to 4.0 p.g/ml for rhinovirus 1A.
HeLa (Ohio) cell growth in the presence of WIN 51711. The in vitro cytotoxicity of WIN 51711 was determined by assessing the effects of the drug on cell growth. The composite data from two experiments are presented in Fig. 3 5 ,ug/ml, but not at 3.1 ,ug/ml. DNA and RNA synthesis, however, was not inhibited at 12.5 ,ug/ml. Since the inhibitory effects of WIN 51711 on virus replication are observed at concentrations substantially below 6.25 jig/ml, and since nonsusceptible picornaviruses as well as other RNA and DNA viruses were able to replicate normally in the presence of 6.2 ,uglml, the antiviral activity cannot be attributed to cytotoxic effects of WIN 51711 on the host cell.
Mechanism of action studies indicate that WIN 51711, like its predecessor arildone (3, 5) , inhibits virus replication by preventing uncoating of the virion and subsequent release of the viral RNA into the cytoplasm (manuscript in preparation). Currently, studies are in progress to further elucidate the mechanism and site of action at the molecular level.
The need exists for a potent, nontoxic drug for the treatment of picornavirus diseases, which range from neonatal sepsis, aseptic meningitis, and hepatitis A to the more common upper respiratory tract disease (colds) (6, 9) . WIN 51711, with its broad in vitro spectrum and in vivo efficacy, is a candidate for development to treat these diseases.
